ClinicalTrials.gov
public full text
Public Domain
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients#888218
- Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer#1373096
- A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours#1153080
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes#849188
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma#1308340
Record · ID 1310218
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive